Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Group 1 - Structure Therapeutics Inc. reported positive results from its phase 2a study of GLP-1R agonist GSBR-1290 for obesity treatment, leading to a phase 2b study initiation in Q4 2024 [1] - The company successfully transitioned from a capsule to a tablet formulation, achieving effective once-daily dosing for weight loss [1] Group 2 - The company plans to combine GLP-1R agonist with other drugs from its pipeline, including APJR agonist ANPA-0073, GIPR selective agonist, and amylin receptor agonist [2] - ANPA-0073 is being developed not only for obesity but also for idiopathic pulmonary fibrosis (IPF), targeting a significant multibillion-dollar market [2] - The development of LPA1R agonist LTSE-2578 for IPF treatment is underway, with a phase 1 randomized study initiated in June 2024 [2] - The company has sufficient cash to progress through several milestones in its development pipeline [2]